Full history for every metric is available with a Kvantra account
Applied Therapeutics, Inc. (APLT)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 10 | 0 | 1 |
| Operating profit | $m | -104 | -98 | |||||
| Net profit | $m | -46 | -94 | -106 | -83 | -120 | -106 | - |
| EPS reported | $ | -0.76 | - | |||||
| Operating cashflow per share | $ | -0.60 | -0.27 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.60 | -0.27 | |||||
| Free cash flow | $m | -84 | -87 | |||||
| Net debt | $m | -79 | -12 | |||||
| Book value equity | $m | 57 | - | |||||
| Book value per share | $ | 0.41 | - | |||||
| Number of shares | m | 139.54 | 145.56 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.10 | -26.72 | |||||
| P/S LTM | x | 262.57 | 14.86 | |||||
| P/FCF LTM | x | -1.42 | -0.17 | |||||
| EV/EBITDA LTM | x | -0.41 | -0.16 | |||||
| EV/Sales LTM | x | 94.21 | 2.92 | |||||
| Earnings Yield LTM | % | -88.41% | -268.93% | |||||
| FCF Yield | % | -70.57% | -584.32% | |||||
| Quality | ||||||||
| ROE | % | -185.29% | -477.81% | |||||
| ROIC | % | -174.41% | -2055.5% | |||||
| Operating margin | % | -22922.9% | -3985.6% | |||||
| Gross margin | % | -10613.0% | -892.30% | |||||
| FCF/Sales | % | -18528.6% | -3874.2% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -95.45% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -30.16 | -34.74 | |||||
| Net Debt/EBITDA | x | 0.73 | 0.23 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -66.46% | -80.37% | |||||
| Net debt/Equity | x | -1.39 | - | |||||
| Gross debt/equity | x | 0.05 | - | |||||
Company overview
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Applied Therapeutics, Inc. (APLT)
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free